Data from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA

• DOI: 10.1158/1078-0432.c.7122860.v1
• Publication Date: 2024-03-15T07:20:58Z
• Authors: Li-Peng Liu; Su-Yu Zong; Ao-Li Zhang; Yuan-Yuan Ren; Ben-Quan Qi; Li-Xian Chang; Wen-Yu Yang; Xiao-Juan Chen; Yu-Mei Chen; Li Zhang; Yao Zou; Ye Guo; Ying-Chi Zhang; Min Ruan; Xiao-Fan Zhu
• Keywords: Risk Stratification; Minimal Residual Disease; Stratification (seeds); Circulating tumor DNA

<div>AbstractPurpose:<p>Patient-tailored minimal residual disease (MRD) monitoring based on circulating tumor DNA (ctDNA) sequencing of leukemia-specific mutations enables early detection relapse for pre-emptive treatment, but its utilization in pediatric acute myelogenous leukemia (AML) is scarce. Thus, we aim to examine the role ctDNA as a prognostic biomarker response treatment AML.</p>Experimental Design:<p>A prospective longitudinal study with 50 children AML was launched, and sequential bone marrow (BM) matched plasma samples were collected. The concordance by next-generation sequencing–based BM-DNA evaluated. In addition, progression-free survival (PFS) overall (OS) estimated.</p>Results:<p>In 195 sample pairs from patients, between 92.8%. Patients undetectable linked improved OS PFS versus detectable last sampling (both <i>P</i> < 0.001). who cleared their post three cycles had similar compared persistently negative (<i>P</i> = 0.728). patients >3 log reduction without clearance associated an 0.564).</p>Conclusions:<p>Thus, ctDNA-based MRD appears be promising option complement assessment AML, wherein continuous negativity have de-escalation subsequent therapy. Importantly, may not require aggressive plan due survival, this needs further delineate.</p></div>